Theracryf Plc (AIM:TCF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2060
+0.0010 (0.49%)
Mar 5, 2026, 9:43 AM GMT
Market Cap4.41M +272.9%
Revenue (ttm)n/a
Net Income-2.01M
EPS-0.00
Shares Out2.15B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume50,000
Average Volume7,346,319
Open0.2060
Previous Close0.2050
Day's Range0.2060 - 0.2060
52-Week Range0.1750 - 0.3000
Beta1.47
RSI41.11
Earnings DateMar 4, 2026

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange London Stock Exchange AIM
Ticker Symbol TCF
Full Company Profile

Financial Performance

Financial Statements